i

A multicenter, openlabel, follow-up study to assess the longterm use of Lacosamide (flexible dose from 200 to 600 mg/day) used as monotherapy in subjects who completed SP0994 and received Lacosamide monotherapy treatment

PHRR160125-001158

SP1042

2015-CT0315

A multicenter, openlabel, follow-up study to assess the longterm use of Lacosamide (flexible dose from 200 to 600 mg/day) used as monotherapy in subjects who completed SP0994 and received Lacosamide monotherapy treatment

a long-term, open-label, follow-up study for subjects being treated with Lacosamide monotherapy at the time of unblinding of SP0994

Regime Classification Priority
2010 - 2016 Health Technology Development Drug Discovery and Development
Start Date Duration in Months Target Completion Date Actual Completion Date
2016-11-22 41 2020-04-22 2020-01-06

Completed

Institution Classification Region LTO #
UCB BioPharma SPRL Private Business Belgium N/A
Institution Classification Region LTO #
PAREXEL Clinical Research (Philippines) Ltd. Corp. Private Business NCR CDRR-NCR-CRO-4
Institution Region
UCB BioPharma SPRL Belgium
Name E-Mail Institution and Institution Address
BryanChristopher Uy-Barreta BryanChristopher.Uy-Barreta@parexel.com 15th Floor Philam Life Tower, 8767 Paseo de Roxas, Makati City, Philippines
Name E-Mail Institution and Institution Address
Maaliddin Biruar Maaliddin.Biruar@parexel.com 15th Floor Philam Life Tower, 8767 Paseo de Roxas, Makati City, Philippines
Name Expertise Affiliation
Artemio Roxas Jr., MD Neurologist The Medical City
Jacqueline C. Dominguez, MD Neurologist St. Luke's Medical Center - Quezon City
Project Location Institutional Ethics Review Board
The Medical City The Medical City - Institutional Review Board
St. Luke's Medical Center - Quezon City St. Luke's Medical Center Institutional Ethics Review Board

partial-onset seizures or generalized tonic-clonic seizures

long-term safety and tolerability of Lacosamide dosed at 200mg/day to 600mg/day (Adverse Events reported)

Unspecified

Completed

  • Bulgaria
  • Finland
  • France
  • Germany
  • Japan
  • Latvia
  • Mexico
  • Poland
  • Russia
  • South Korea
  • Sweden
  • Switzerland
  • Ukraine

Clinical Trial

SP1042

20150904113046

2016-01-05

0000-00-00

16

4

Unspecified

2016-11-22

Inclusion criteria
To be eligible to participate in this study, all of the following criteria must be met:
1. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written Informed Consent form is signed and dated by the subject or by the parent(s) or legal representative. The Informed Consent form or a specific Assent form, where required, will be signed and dated by minors.
2. Subject/legal representative is considered reliable and capable of adhering to the protocol, visit schedule, and medication intake according to the judgment of the investigator.
3. Subject has completed the Termination Visit of SP0994 and has been treated with LCM monotherapy.

Exclusion criteria
Subjects are not permitted to enroll in the study if any of the following criteria are met:
1. Subject is receiving any investigational drugs or using any experimental devices in addition to LCM.
2. Subject experienced a seizure at the third target dose (ie, LCM 600 mg/day) during SP0994.
3. Subject requires another AED for the treatment of seizures.
4. Subject meets a “must” withdrawal criterion for the previous study, SP0994.
5. Subject is experiencing an ongoing SAE from the previous study, SP0994.
6. Female subject who is pregnant or nursing, and/or a woman of childbearing potential who is not surgically sterile, 2 year postmenopausal or does not practice one highly effective method
of contraception (according to ICH guidance defined as those that result in a failure rate of less than 1% per year when used consistently and correctly), unless sexually abstinent, for the duration of the study.

Interventional

Lacosamide

Subject numbers were assigned at the beginning of SP0993 and will remain the same in SP1042.

Date Amendment Classification Reason
2017-04-17 Amendments related to the protocol Informed consent
2017-08-22 Amendments related to the protocol
2018-07-13 Amendments related to the protocol Informed consent
2018-10-29 Amendments related to the protocol Informed consent

Randomized

Open Label

Unspecified

Parallel

assess the long-term safety and tolerability of LCM dosed at  200mg/day to 600mg/day when used as monotherapy in subjects, with partial-onset seizures or generalized tonic-clonic seizures (without clear focal origin), who completed SP0994 and received LCM

Phase III

Utilization Utilization Info
Publication
Oral Presentation
Drug Literature
Posters
Others
©2021 HERDIN PLUS. All rights reserved. | Contact Us | Keep up to date